2367 / 2605
2367 / 2605
• In design-phase:
The
PC05 neoadjuvant protocol
(preopera3vely) for
pa3ents with resectable and marginally
resectable cancers.
Randomiza3on between:
–
59.40CGE to gross disease
–
50.40CGE to regional nodes with a gross disease
boost to 59.40CGE
C. Nichols – cont.:
